Same-shift, Phenotypic Bacterial Diagnostics—Powered by Phage Amplification
Cobio Diagnostics
Cobio is developing a next‑generation, phage‑amplified diagnostic platform for rapid bacterial identification, antimicrobial susceptibility testing, and minimum inhibitory concentration determination directly from clinical specimens.
Our approach is phenotypic, instrument‑agnostic, and designed to scale across pathogens and healthcare environments — from advanced clinical laboratories to resource‑limited and austere settings.
Why Cobio Exists
The global rise of antimicrobial resistance is not an abstract threat — it is a daily reality in hospitals and communities worldwide. For the founders of Cobio Diagnostics, this challenge is both professional and personal.
That perspective reinforces our commitment to building practical, phenotypic diagnostic tools that support earlier targeted therapy, responsible antibiotic use, and improved patient outcomes across healthcare settings.
The method is scalable, applicable to low-tech settings, and is differentiated from current diagnostic standards by its reduced time to results, reduction of costs, and wide applicability to many pathogens.
